Fig. 8

High expression of BID is frequent in human tumors while Chr22q11 amplification is a rare event. A Frequency of co-amplification of Chr22q11 genes (left panel, red bars), BID copy number gains (middle panel, blue bars) and BID mRNA overexpression (right panel, green bars) in human malignancies, as found in the COSMIC database. Asterisks denote significant differences with the entire tumor cohort (indicated by lighter bars) ***p<0.001, **p<0.01, *p<0.05 (two-tailed z-score). B FISH analysis of a tumor harboring Chr22q11 amplification. Probes for the HIRA, CRKL and MAPK1 (upper panel) or for HIRA and SHANK3 (lower panel) were used. The sample corresponded to a 54-year-old, non-smoker woman with squamous carcinoma of the lung and showed an average of 8 copies of HIRA, CRKL and MAPK1 genes with a 3.0 ratio to the telomeric probe. C Levels of BID mRNA, as quantified by nCounter, in FFPE blocks from a cohort of 67 advanced lung tumors (white dots), AURKB/TTKi-sensitive (green dot) and AURKB/TTKi-resistant (blue dot) cell lines. The names of the cell lines are indicated. The solid and dotted lines indicate the geomean + 2xSD and + SD, respectively. D Levels of BID mRNA, as quantified by RT-Q-PCR in FFPE blocks from a cohort of 94 tumor samples (white dots, Table S14), AURKB/TTKi-sensitive (green dots) and AURKB/TTKi-resistant (blue dots) cell lines. The names of some cell lines are shown on the plot. The solid and dotted lines indicate the geomean + 2xSD and + SD, respectively, of the FFPE tumor samples